ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)." [1] This study, led by Ani Pazhava, MD, and colleagues from the Mayo Clinic and University Hospitals Cleveland Medical Center and SkylineDx, highlights the potential of the Merlin test to refine clinical decision-making in head and neck melanoma patients.
Health Professionals
Moffitt Study Finds New Immunotherapy Strategy for Enhancing Melanoma Treatment
Recent advancements in the melanoma treatment paradigm have drastically improved outcomes and changed the diagnosis of metastatic melanoma from a horrible prognosis to a potentially curable one. DocWire News spoke to John Fruehauf, MD, field medical director at Evolent, about how new therapies have improved the landscape of metastatic melanoma care.
Subcutaneous Nivolumab Reduces Burden of Melanoma Care, Expert Says
In December, the U.S. Food and Drug Administration (FDA) approved nivolumab and hyaluronidase-nvhv (Opdivo Qvantig) for subcutaneous injection across all of nivolumab’s approved adult solid tumor indications, including melanoma.
Report Highlights Role of Cancer-Associated Fibroblasts in Melanoma Metastases
The study could open the door to potential novel therapeutic targets.